Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 3/20 | 0.45 |
| ▸ | BUB1 | O43683 | 1/20 | 0.43 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.43 |
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
| ▸ | RIPK3 | Q9Y572 | 10/20 | 0.42 |
| ▸ | GRM5 | P41594 | 1/20 | 0.40 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25207231 | 0.84 | PARP10 (0.51) | MAPKAPK2BUB1PARP10PARP1PARP11 | |
| SCHEMBL17847604 | 0.75 | PKN2 (0.56) | MAPKAPK2PARP10PARP1RIPK3PARP11 | |
| SCHEMBL17847644 | 0.73 | BUB1 (0.49) | MAPKAPK2BUB1PARP10PARP1RIPK3 | |
| SCHEMBL25211238 | 0.72 | CDC7 (0.39) | RIPK3HSP90AA1HSP90AB1GRM2 | |
| SCHEMBL25203499 | 0.72 | POLB (0.38) | BUB1 | |
| SCHEMBL798998 | 0.72 | RIPK3 (0.44) | MAPKAPK2BUB1PARP10PARP1RIPK3 | |
| SCHEMBL6110112 | 0.71 | CDC7 (0.72) | MAPKAPK2BUB1RIPK3 | |
| SCHEMBL17847590 | 0.70 | RIPK3 (0.46) | RIPK3HSP90AA1HSP90AB1GRM2 | |
| SCHEMBL155162 | 0.70 | BUB1 (0.46) | MAPKAPK2BUB1PARP10PARP1RIPK3 | |
| SCHEMBL30625735 | 0.68 | CDC7 (0.40) | MAPKAPK2BUB1PARP10PARP1PARP11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10301306-B2 | Substituted dihydro-1H-pyrrolo[3,2-c]pyridin-4(5H)-ones as RIPK3 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-05-28 | — | — | US | disclosed |
| US-10301306-B2 | Substituted dihydro-1H-pyrrolo[3,2-c]pyridin-4(5H)-ones as RIPK3 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-05-28 | — | — | US | disclosed |
| US-20170362219-A1 | SUBSTITUTED DIHYDRO-1H-PYRROLO[3,2-C]PYRIDIN-4(5H)-ONES AS RIPK3 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-12-21 | — | — | US | disclosed |
| US-20170362219-A1 | SUBSTITUTED DIHYDRO-1H-PYRROLO[3,2-C]PYRIDIN-4(5H)-ONES AS RIPK3 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-12-21 | — | — | US | disclosed |
| US-20170362219-A1 | SUBSTITUTED DIHYDRO-1H-PYRROLO[3,2-C]PYRIDIN-4(5H)-ONES AS RIPK3 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-12-21 | — | — | US | disclosed |
| WO-2016100166-A1 | SUBSTITUTED DIHYDRO-1H-PYRROLO[3,2-c]PYRIDIN-4(5H)-ONES AS RIPK3 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-06-23 | — | — | WO | disclosed |
| WO-2016100166-A1 | SUBSTITUTED DIHYDRO-1H-PYRROLO[3,2-c]PYRIDIN-4(5H)-ONES AS RIPK3 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362219-A1 | SUBSTITUTED DIHYDRO-1H-PYRROLO[3,2-C]PYRIDIN-4(5H)-ONES AS RIPK3 INHIBITORS | RIPK3, RIPK1, RIPK4 | MAPKAPK2 99/4885BUB1 479/4885PARP10 332/4885 |
| US-10301306-B2 | Substituted dihydro-1H-pyrrolo[3,2-c]pyridin-4(5H)-ones as RIPK3 inhibitors | RIPK3, RIPK1, RIPK4 | MAPKAPK2 99/4885BUB1 479/4885PARP10 332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.